APOC3 Inhibitors

Author(s):

Peter Toth, MD, PhD, FCCP, FESC, FAHA, FACC ,James Underberg, MS, MD, FACP, FACPM, FASPC, FASH, FNLA

Key Takeaways

Delayed FCS diagnosis can lead to exacerbated cardiovascular and metabolic consequences, increasing atherosclerosis and cardiovascular disease risk.
Persistent hypertriglyceridemia from untreated FCS may result in chronic pancreatitis, diabetes, and liver disease.
Early intervention is essential to manage triglyceride levels, prevent severe complications, and improve patient outcomes.

Panelists discuss important novel therapies emerging for familial chylomicronemia syndrome (FCS), focusing on APOC3 inhibitors, including small interfering RNA (siRNA) and antisense oligonucleotides (ASO), and their potential to address the underlying lipid metabolism dysfunction in patients with FCS.

EP: 1.Overview of FCS

EP: 2.Severe Hypertriglyceridemia

EP: 3.Pathophysiology of FCS

EP: 4.Early Diagnosis

EP: 5.Genetic Testing

EP: 6.Metabolic Disorders and Delayed Diagnosis

EP: 7.FCS’ Affect on Quality of Life

EP: 8.Multidisciplinary Approach to Managing FCS

Now Viewing

EP: 9.APOC3 Inhibitors

Video content above is prompted by the following:

Can you review important novel therapies for FCS that are APOC3 inhibitors (siRNA and ASO) that have recently emerged?